Aadi Bioscience, Inc.
NASDAQ: AADI0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- David J. Lennon
- Employees
- 53
- Headquarters
- Pacific Palisades, United States
- IPO year
- 2018
- Market cap
- $94.9M
- Website
- https://aadibio.com
Loading AADI…
Loading profile data…Frequently asked questions about AADI
What does Aadi Bioscience, Inc. (AADI) do?
Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing highly targeted therapies for cancers defined by specific genetic alterations within the mTOR pathway. Its flagship drug candidate, FYARRO, is an investigational therapeutic composed of sirolimus conjugated with albumin. Aadi is active...
Where does AADI trade?
Aadi Bioscience, Inc. (AADI) trades on the NASDAQ Capital Market.
What sector is AADI in?
Aadi Bioscience, Inc. (AADI) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Aadi Bioscience, Inc.?
David J. Lennon is the chief executive officer of Aadi Bioscience, Inc. (AADI).
Where is Aadi Bioscience, Inc. headquartered?
Aadi Bioscience, Inc. is headquartered in United States.
Does AADI pay a dividend?
Aadi Bioscience, Inc. (AADI) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did AADI go public?
Aadi Bioscience, Inc. (AADI) completed its initial public offering in 2018.